GlassScriptPhysician profile
Lauren M Mader
NPI 1578180295
$2,552.08
in general payments reported to CMS, 2019-2025
34 companies · $308 in 2025
The $308 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $308 · 2022: $779 · 2023: $767 · 2024: $391 · 2025: $308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,367 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,366.64 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $336.27 | 2021-2023 | Enhertu |
| Lilly USA, LLC | $247.35 | 2021-2024 | Verzenio, Jaypirca |
| Incyte Corporation | $158.15 | 2022-2024 | Jakafi |
| Novartis Pharmaceuticals Corporation | $145.31 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $143.64 | 2022-2024 | Keytruda, Lynparza |
| Ethicon US, LLC | $125.93 | 2025 | Certus 140 |
| Penumbra, INC. | $116.30 | 2025 | Ruby Coil |
| Seagen INC. | $110.97 | 2022-2023 | Tivdak, Adcetris, Tukysa |
| Eisai INC. | $101.60 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $100.88 | 2022-2024 | Alunbrig, Hyqvia |
| Sanofi-Aventis U.S. LLC | $99.00 | 2023 | |
| Amgen INC. | $87.87 | 2021-2022 | |
| Pfizer INC. | $85.86 | 2022-2024 | |
| Gilead Sciences, INC. | $85.52 | 2022-2025 | Trodelvy |
| Astrazeneca Pharmaceuticals LP | $75.25 | 2022-2024 | Enhertu |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $58.73 | 2021-2024 | Talvey, Tecvayli |
| E.R. Squibb & Sons, L.L.C. | $57.13 | 2023-2025 | Opdivo |
| Bayer Healthcare Pharmaceuticals INC. | $46.78 | 2022-2023 | |
| Genentech USA, INC. | $43.73 | 2022 | |
| Alexion Pharmaceuticals, INC. | $32.76 | 2022-2024 | Ultomiris |
| Kyowa Kirin, INC. | $31.51 | 2023-2024 | Poteligeo |
| Abbvie INC. | $31.30 | 2024 | |
| Servier Pharmaceuticals LLC | $24.93 | 2022 | |
| Genzyme Corporation | $22.96 | 2023 | |
| Celgene Corporation | $22.09 | 2022 | |
| Emd Serono, INC. | $21.07 | 2023 | Bavencio |
| Medtronic, INC. | $19.21 | 2024 | Mvp |
| Morphosys, US INC. | $18.72 | 2023 | Monjuvi |
| Jazz Pharmaceuticals INC. | $18.27 | 2024 | |
| Pharmacyclics LLC, An Abbvie Company | $17.36 | 2021 | |
| Pharmacosmos Therapeutics INC. | $17.30 | 2023 | Monoferric |
| Sumitomo Pharma America, INC. | $16.95 | 2023 | Orgovyx |
| Deciphera Pharmaceuticals INC. | $15.77 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.61 | 2023 | Gilotrif |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Mader listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.